A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors
Latest Information Update: 19 Apr 2022
Price :
$35 *
At a glance
- Drugs NOV 10 (Primary)
- Indications Breast cancer; Head and neck cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Apr 2022 Results published in the Molecular Cancer Therapeutics
- 24 Oct 2018 Status changed from recruiting to completed.
- 06 Feb 2018 Planned End Date changed from 25 Dec 2018 to 6 Mar 2019.